H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
References<br />
1. Petersdorf EW, Malkki M, Gooley TA, Martin PJ, Guo Z.<br />
MHC hap<strong>lo</strong>type matching for unrelated hematopoietic cell<br />
transplantat<strong>io</strong>n. PLoS Med. 2007;4(1):e8.<br />
2. Ferrara GB, Bacigalupo A, Lamparelli T, Lanino E, Delfino L,<br />
Morabito A, et al. Bone marrow transplantat<strong>io</strong>n from unrelated<br />
donors: the impact of mismatches with substitut<strong>io</strong>ns at<br />
posit<strong>io</strong>n 116 of the human leukocyte antigen class I heavy<br />
chain. B<strong>lo</strong>od. 2001;98(10):3150-5.<br />
3. Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H,<br />
Saji H, et al. High-risk HLA allele mismatch combinat<strong>io</strong>ns<br />
responsible for severe acute graft-versus-host disease and implicat<strong>io</strong>n<br />
for its molecular mechanism. B<strong>lo</strong>od. 2007;110(7):<br />
2235-41.<br />
4. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre<br />
G, et al. Severe events in donors after al<strong>lo</strong>geneic hematopoietic<br />
stem cell donat<strong>io</strong>n. Haemato<strong>lo</strong>gica. 2009;94(1):94-101.<br />
5. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, et al.<br />
Extended fol<strong>lo</strong>w-up of methotrexate-free immunosuppress<strong>io</strong>n<br />
using sirolimus and tacrolimus in related and unrelated donor<br />
peripheral b<strong>lo</strong>od stem cell transplantat<strong>io</strong>n. B<strong>lo</strong>od. 2007;109(7):<br />
3108-14.<br />
6. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M,<br />
Zander AR, et al. Standard graft-versus-host disease prophylaxis<br />
with or without anti-T-cell g<strong>lo</strong>bulin in haematopoietic<br />
cell transplantat<strong>io</strong>n from matched unrelated donors: a randomised,<br />
open-label, multicentre phase 3 trial. Lancet Oncol.<br />
2009;10(9):855-64.<br />
7. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE,<br />
Di Barto<strong>lo</strong>meo P, et al. Antithymocyte g<strong>lo</strong>bulin for graft-versus-host<br />
disease prophylaxis in transplants from unrelated<br />
donors: 2 randomized studies from Gruppo Italiano Trapianti<br />
Midol<strong>lo</strong> Osseo (GITMO). B<strong>lo</strong>od. 2001;98(10):2942-7.<br />
8. Bacigalupo A, Lamparelli T, Baris<strong>io</strong>ne G, Bruzzi P, Guidi S,<br />
Alessandrino PE, et al. Thymog<strong>lo</strong>bulin prevents chronic graftversus-host<br />
disease, chronic lung dysfunct<strong>io</strong>n, and late transplant-related<br />
mortality: <strong>lo</strong>ng-term fol<strong>lo</strong>w-up of a randomized<br />
trial in patients undergoing unrelated donor transplantat<strong>io</strong>n.<br />
B<strong>io</strong>l B<strong>lo</strong>od Marrow Transplant. 2006;12(5):560-5.<br />
9. Byrne JL, Stainer C, Cull G, Haynes AP, Bessell EM, Hale G,<br />
et al. The effect of the serotherapy regimen used and the marrow<br />
cell dose received on reject<strong>io</strong>n, graft-versus-host disease<br />
and outcome fol<strong>lo</strong>wing unrelated donor bone marrow transplantat<strong>io</strong>n<br />
for leukaemia. Bone Marrow Transplant. 2000;<br />
25(4):411-7.<br />
10. Petersdorf EW, Anasetti C, Martin PJ, Gooley T, Radich J,<br />
Malkki M, et al. Limits of HLA mismatching in unrelated<br />
London, United Kingdom, June 9-12, 2011<br />
hematopoietic cell transplantat<strong>io</strong>n. B<strong>lo</strong>od. 2004;104(9):<br />
2976-80.<br />
11. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL,<br />
Eapen M, et al. High-resolut<strong>io</strong>n donor-recipient HLA matching<br />
contributes to the success of unrelated donor marrow transplantat<strong>io</strong>n.<br />
B<strong>lo</strong>od. 2007;110(13):4576-83.<br />
12. La Nasa G, Caocci G, Arg<strong>io</strong>lu F, Giardini C, Locatelli F, Vacca<br />
A, et al. Unrelated donor stem cell transplantat<strong>io</strong>n in adult<br />
patients with thalassemia. Bone Marrow Transplant. 2005;<br />
36(11):971-975.<br />
13. Crocch<strong>io</strong><strong>lo</strong> R, Zino E, Vago L, Oneto R, Bruno B, Pollichieni S,<br />
et al. Nonpermissive HLA-DPB1 disparity is a significant independent<br />
risk factor for mortality after unrelated hematopoietic<br />
stem cell transplantat<strong>io</strong>n. B<strong>lo</strong>od. 2009;114(7):1437-44.<br />
14. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT,<br />
et al. Donor select<strong>io</strong>n for natural killer cell receptor genes leads<br />
to super<strong>io</strong>r survival after unrelated transplantat<strong>io</strong>n for acute<br />
mye<strong>lo</strong>genous leukemia. B<strong>lo</strong>od. 2010;116(14):2411-9.<br />
15. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM,<br />
Ma<strong>lo</strong>ney DG, et al. Hematopoietic cell transplantat<strong>io</strong>n (HCT)specific<br />
comorbidity index: a new tool for risk assessment<br />
before al<strong>lo</strong>geneic HCT. B<strong>lo</strong>od. 2005;106(8):2912-9.<br />
16. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T,<br />
Dini G, et al. Al<strong>lo</strong>geneic and auto<strong>lo</strong>gous transplantat<strong>io</strong>n for<br />
haemato<strong>lo</strong>gical diseases, solid tumors and immune disorders:<br />
current practice in Europe 2009. Bone Marrow Transplant.<br />
2010;45(2):219-34.<br />
17. Lim Z, Brand R, Martino R, Van Biezen A, Finke J, Bacigalupo<br />
A, et al. Al<strong>lo</strong>geneic hematopoietic stem-cell transplantat<strong>io</strong>n for<br />
patients 50 years or older with mye<strong>lo</strong>dysplastic syndromes or<br />
secondary acute mye<strong>lo</strong>id leukemia. J Clin Oncol. 2010;<br />
28(3):405-11.<br />
18. Ho VT, Kim HT, Aldridge J, Liney D, Kao G, Armand P, et al.<br />
Use of Matched Unrelated Donors Compared with Matched<br />
Related Donors Is Associated with Lower Relapse and<br />
Super<strong>io</strong>r Progress<strong>io</strong>n-Free Survival after Reduced-Intensity<br />
Condit<strong>io</strong>ning Hematopoietic Stem Cell Transplantat<strong>io</strong>n. B<strong>io</strong>l<br />
B<strong>lo</strong>od Marrow Transplant. 2010.<br />
19. Bacigalupo A, Socie’ G, Lanino E, Prete A, Locatelli F,<br />
Locasciulli A, et al. Fludarabine, cyc<strong>lo</strong>phosphamide, antithymocyte<br />
g<strong>lo</strong>bulin, with or without <strong>lo</strong>w dose total body irradiat<strong>io</strong>n,<br />
for alternative donor transplants, in acquired severe<br />
aplastic anemia: a retrospective study from the EBMT-SAA<br />
working party. Haemato<strong>lo</strong>gica. 2010;95(6):976-82.<br />
20. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE,<br />
Weisdorf DJ, et al. Peripheral b<strong>lo</strong>od grafts from unrelated<br />
donors are associated with increased acute and chronic graftversus-host<br />
disease without improved survival. B<strong>io</strong>l B<strong>lo</strong>od<br />
Marrow Transplant. 2007;13(12):1461-8.<br />
Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1) | 55 |